Drake University’s pharmacy college honors PTCB executive director, CEO
WASHINGTON Drake University’s College of Pharmacy has given its 2010 Lawrence C. and Delores M. Weaver Medal of Honor to the leader of a pharmacy technician group.
The Pharmacy Technician Certification Board announced Tuesday that executive director and CEO Melissa Murer Corrigan had received the medal, which the college, in Des Moines, Iowa, gives to individuals whom it considers to show dedication to the pharmacy profession. Murer Corrigan has served in her position at the PTCB since its 1995 inception.
“Under Melissa’s guidance and leadership, PTCB has positioned pharmacy technicians as an integral part of enhanced pharmacy practice and improved patient care,” American Pharmacists Association EVP and CEO Thomas Menighan said. “Trained, skilled pharmacy technicians empower pharmacists to spend time with patients to optimize their drug therapy and achieve the most positive outcomes possible.”
Sandoz to acquire Oriel Therapeutics
HOLZKIRCHEN, Germany Sandoz got its hands on a collection of generic drug candidates Monday as it agreed to acquire privately owned U.S. drug maker Oriel Therapeutics, the generics arm of Swiss drug maker Novartis said. Financial terms of the deal were not disclosed.
Oriel focuses on drugs for respiratory conditions, such as asthma and chronic obstructive pulmonary disease, and the deal gives Sandoz access to development projects such as Solis, a dry powder inhaler that uses Oriel’s FreePath drug-delivery technology.
“Oriel is a strong strategic fit with Sandoz, and the acquisition is expected to support our strategy of increasing the number of differentiated, higher-value products in our development pipeline,” Sandoz division head Jeff George said. “One of our strategic objectives is to offer fully substitutable generic versions of key branded medicines, including respiratory medicines.”
Emdeon affirms e-prescribing for controlled substances is a ‘practical necessity’
NASHVILLE, Tenn. Electronic prescribing network Emdeon is supporting the approval of security standards for e-prescribing of controlled substances, Emdeon said last week.
The company, which calls itself the only e-prescribing network with market-based experience in controlled substances, said it was committed to helping the Drug Enforcement Administration and healthcare industry to implement the interim final rule for e-prescribing the drugs. Controlled substances include prescription drugs for such conditions as chronic pain and psychiatric disorders that are prone to abuse and diversion.
“Our market experience during the Massachusetts Department of Public Health research project indicates that electronic prescribing for controlled substances is safe and a practical necessity,” Emdeon CEO George Lazenby said. “The potential impact is tremendous.”
The Agency for Health Research and Quality, a government agency, funded the MDPH research project with the aim of demonstrating the technological feasibility and potential benefits to patient safety in e-prescribing of controlled substances.